Screening Eligibility:

          -  Patients with histologically confirmed WHO Grade III or IV malignant glioma

          -  Scheduled for definitive surgical resection of suspected HGG (biopsy only subjects are
             not eligible for this study)

        Post-Surgical Resection Eligibility

          -  Histologically confirmed WHO Grade III or IV malignant glioma

          -  Residual post-surgical disease burden < 3 cm as defined by longest perpendicular
             diameter of contrast enhancing tumor on post-operative MRI Karnofsky Performance
             Status (KPS) of > 60% (KPS for > 16 years of age) or Lansky performance Score (LPS) of
             ≥ 60 (LPS for ≤ 16 years of age) assessed within 2 weeks prior to registration

          -  Bone Marrow: ANC (Absolute neutrophil count) ≥ 1000/µl (unsupported); Platelets ≥
             100,000/µl (unsupported for at least 3 days); Hemoglobin > 8 g/dL (may be supported)

          -  Renal:Serum creatinine ≤ upper limit of institutional normal Hepatic: Bilirubin ≤ 1.5
             times upper limit of institutional normal for age. SGPT (ALT) ≤ 3 times upper limit of
             institutional normal for age. SGOT (AST) ≤ 3 times upper limit of institutional normal
             for age.

          -  Signed informed consent according to institutional guidelines.

          -  Patient or patient guardian consent to PBSC harvest following registration.

          -  Subjects of childbearing or child-fathering potential must be willing to use medically
             acceptable forms of birth control while being treated on this study.

          -  Subjects with post-surgical neurological deficits should have deficits that are stable
             for a minimum of 1 week prior to registration.

        Prior to 1st Vaccine

        - Off corticosteroids or weaning to a minimal/stable dose of replacement steroids ≤ 4
        mg/day within 1 week of scheduled DC vaccination.

        Exclusion Criteria:

          -  HGG biopsy only subjects are not eligible for this study

          -  Midline unresectable tumors

          -  Gliomatosis Cerebri

          -  Residual post-surgical disease burden > 3 cm as defined by longest perpendicular
             diameter of contrast enhancing tumor on MRI.

          -  Pregnant or need to breast feed during the study period (Negative serum pregnancy test
             required).

          -  Known autoimmune or immunosuppressive disease or human immunodeficiency virus
             infection.

          -  Subjects with significant renal, cardiac (congestive cardiac failure, myocardial
             infarction, myocarditis), pulmonary, hepatic or other organ dysfunction.

          -  Subjects who require corticosteroids above physiologic doses (>4mg/day or equivalent
             dexamethasone).

          -  Severe or unstable concurrent medical conditions.

          -  Prior allergic reaction to TMZ, GM-CSF, or Td

          -  Subjects who are unwilling or unable to receive treatment and undergo follow-up
             evaluations at the enrolled Sunshine Project Consortium treatment site.